Swati Ahuja1, Ankit Uniyal2, Ansab Akhtar3, Sangeeta Pilkhwal Sah4. 1. Pharmacology Division, University Institute of Pharmaceutical Sciences (UIPS), Panjab University, UGC Centre of Advanced Study (UGC-CAS), Chandigarh, India. Electronic address: swatiahuja1993@gmail.com. 2. Pharmacology Division, University Institute of Pharmaceutical Sciences (UIPS), Panjab University, UGC Centre of Advanced Study (UGC-CAS), Chandigarh, India. Electronic address: ankituniyal1994rsb@gmail.com. 3. Pharmacology Division, University Institute of Pharmaceutical Sciences (UIPS), Panjab University, UGC Centre of Advanced Study (UGC-CAS), Chandigarh, India. Electronic address: ansabakhtar@gmail.com. 4. Pharmacology Division, University Institute of Pharmaceutical Sciences (UIPS), Panjab University, UGC Centre of Advanced Study (UGC-CAS), Chandigarh, India. Electronic address: spilkhwal@rediffmail.com.
Abstract
BACKGROUND: Obesity is commonly found to be co-morbid with type 2 Diabetes Mellitus. In obese diabetic patients, TLR-2 receptor induced inflammation leads to the development of insulin resistance (IR). Furthermore, the IR is considered to be the most important cause for promoting cognitive decline which is evident in brain of patients with Alzheimer's disease related dementia (ADRD). METHODS: In this study, the effect of α-lipoic acid (ALA) has been examined in rodent model of zymosan induced insulin resistance and cognitive deficits, targeting at TLR-2 signalling. TLR-2 agonist, Zymosan initiates inflammatory cascade, resulting in IR and cognitive dysfunction. Zymosan (50 mg/kg ip) was given to mice on 1st, 8th, 15th and 22nd day to induce IR which was confirmed by hyperglycaemia, hyperinsulinemia, hyperlipidimea, increased glycated haemoglobin and HOMA-IR. Further the cognitive performance was assessed in Morris water maze revealing cognitive deficit in zymosan treated mice. RESULTS: Daily treatment with ALA for 28 days (50, 100, 200 mg/kg, ip) significantly improved insulin sensitivity and cognitive performance in mice by decreasing insulin resistance, corticosterone, IL-6 levels, acetylcholinesterase enzyme activity and oxidative stress in liver, cortex and hippocampus. ALA also increased adiponectin level and reduced body weight. Combination of ALA (100 mg/kg, ip) with metformin (100 mg/kg, ip) exhibited a potentiating effect in improving cognitive performance and insulin signalling. CONCLUSION: The findings of the study supported the hypothesis that TLR-2 induced inflammation leads to insulin resistance and cognitive impairment and provides an evidence for the therapeutic effect of ALA in IR and ADRD patients.
BACKGROUND: Obesity is commonly found to be co-morbid with type 2 Diabetes Mellitus. In obese diabeticpatients, TLR-2 receptor induced inflammation leads to the development of insulin resistance (IR). Furthermore, the IR is considered to be the most important cause for promoting cognitive decline which is evident in brain of patients with Alzheimer's disease related dementia (ADRD). METHODS: In this study, the effect of α-lipoic acid (ALA) has been examined in rodent model of zymosan induced insulin resistance and cognitive deficits, targeting at TLR-2 signalling. TLR-2 agonist, Zymosan initiates inflammatory cascade, resulting in IR and cognitive dysfunction. Zymosan (50 mg/kg ip) was given to mice on 1st, 8th, 15th and 22nd day to induce IR which was confirmed by hyperglycaemia, hyperinsulinemia, hyperlipidimea, increased glycated haemoglobin and HOMA-IR. Further the cognitive performance was assessed in Morris water maze revealing cognitive deficit in zymosan treated mice. RESULTS: Daily treatment with ALA for 28 days (50, 100, 200 mg/kg, ip) significantly improved insulin sensitivity and cognitive performance in mice by decreasing insulin resistance, corticosterone, IL-6 levels, acetylcholinesterase enzyme activity and oxidative stress in liver, cortex and hippocampus. ALA also increased adiponectin level and reduced body weight. Combination of ALA (100 mg/kg, ip) with metformin (100 mg/kg, ip) exhibited a potentiating effect in improving cognitive performance and insulin signalling. CONCLUSION: The findings of the study supported the hypothesis that TLR-2 induced inflammation leads to insulin resistance and cognitive impairment and provides an evidence for the therapeutic effect of ALA in IR and ADRD patients.
Authors: Mateusz Maciejczyk; Ewa Żebrowska; Miłosz Nesterowicz; Elżbieta Supruniuk; Barbara Choromańska; Adrian Chabowski; Małgorzata Żendzian-Piotrowska; Anna Zalewska Journal: J Inflamm Res Date: 2022-04-08